Home Blog Page 227
Trovagene’s Next Generation SamplingSM technology can be used to interrogate an ultra-short DNA sequence (~30 bp)
Oncology has risen to the forefront of genomic profiling, which is being used to identify actionable driver mutations and other markers. These markers can help clinicians design therapies and monitor patient responses, and they may be revealed by means of next-generation sequencing (NGS), a catch-all term describing massive parallel sequencing technologies generating gigabases of data. NGS is already established as...
It will be absolutely essential for doctors to explain to their patients why some types of genomic information might be clinically actionable while other kinds are inconsequential. [© Science Photo/Fotolia]
It seems every week that a new publication extols the benefits of next-generation sequencing (NGS), often from sequencing the genome of a medically relevant organism in record time or identifying the polymorphisms that may lead to drug resistance in cancer. One could make an educated guess that NGS is poised to tackle almost any clinical issue facing precision medicine....
With next-generation sequencing
Conventional wisdom has steered scientists for many years toward the assumption that disease-triggering genetic mutations were inherited by offspring from existing mutations within parental DNA, and that these mutations reside within all somatic cells, eventually emerging due to some perturbation of the cellular environment. However, over the past several years experimental and genomic data has shown that many of...

The April issue of Clinical OMICs is available now! Check it out by clicking on the link below.

A new MRI technique shows that mucin-attached sugars generate a high MRI signal (left) compared to cancerous cells (right) [Xiaolei Song/Johns Hopkins Medicine]
The holy grail of clinical diagnostics would be a completely noninvasive technique that can identify disease with exceptional accuracy. Unfortunately, science has yet to achieve this almost essential goal. However, new research from Johns Hopkins scientists may provide the crucial data required to take a big leap toward complete noninvasive diagnoses. Imaging tests such as mammograms or CT scans can...
Source: iStock/© omgimages
Ten biopharma companies have joined together to create the Genomics Expert Network for Enterprises (GENE) Consortium, which will oversee a year-long trial designed to integrate industry expertise into the 100,000 Genomes Project—the U.K.’s effort to catapult itself to global leadership in genetic research into cancer and rare diseases. Through the GENE Consortium, the companies will work to discover how best...
Source: iStock/© SilverV
IntegraGen will oversee high-throughput sequencing activities for the National Reference Center (NRC) and microbiological collections at the Institut Pasteur. The partnership’s primary objective, according to IntegraGen, is to increase access to next-generation sequencing technologies for the 15 NRCs and the institute’s microbiology collection. The partnership also aims to establish reference tools for the typing of bacterial, viral, and fungal strains. Additionally,...
Source: © olly/Fotolia
Dako, an Agilent Technologies company specializing in providing cancer diagnostics, said today it has again expanded a three-year-old collaboration with Amgen focused on companion diagnostics. The value of the expanded collaboration and other financial terms were not disclosed. Dako said the expanded “multi-year” collaboration will allow both companies to benefit from knowledge-sharing within drug-diagnostic R&D, particularly in relation to companion...
Source: © inkaone/Fotolia
Qiagen acquired AdnaGen’s circulating tumor cell (CTC) enrichment technology to boost its capabilities in liquid biopsies. Separately, the company formed a partnership with Tokai Pharmaceuticals to combine its new CTC technology with a molecular assay to co-develop and commercialize a companion diagnostic for Tokai’s galeterone, which is in late-stage clinical trials for treatment of castration-resistant prostate cancer (CRPC). The...
Richard Scheller
Less than a month after winning its first FDA authorization, 23andMe is expanding beyond direct-to-consumer genetic testing by creating a new therapeutics group, and appointing Genentech’s recently retired evp of research and early development to lead the new unit. Richard Scheller, Ph.D., has been named 23andMe’s CSO and head of therapeutics, effective at the beginning of next month. At the...
Scroll Up